Cas:1350738-87-2 7-Bromo-3,4-dihydro-2H-benzo[b][1,4]oxazine hydrochloride manufacturer & supplier

Chemical Name:7-Bromo-3,4-dihydro-2H-benzo[b][1,4]oxazine hydrochloride

CAS.NO:1350738-87-2

Synonyms:7-Bromo-3,4-dihydro-2H-1,4-benzoxazine hydrochloride (1:1);2H-1,4-Benzoxazine, 7-bromo-3,4-dihydro-, hydrochloride (1:1);7-bromo-3,4-dihydro-2H-1,4-benzoxazine,hydrochloride

Molecular Formula:C₈H₉BrClNO

Molecular Weight:250.520

HS Code:2934999090

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:N/A

Index of Refraction:

PSA:21.26000

Exact Mass:248.955597

LogP:3.19340

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like 7-Bromo-3,4-dihydro-2H-1,4-benzoxazine hydrochloride (1:1) chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,7-bromo-3,4-dihydro-2H-1,4-benzoxazine,hydrochloride physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,2H-1,4-Benzoxazine, 7-bromo-3,4-dihydro-, hydrochloride (1:1) Use and application,7-bromo-3,4-dihydro-2H-1,4-benzoxazine,hydrochloride technical grade,usp/ep/jp grade.

Related News: Mankind Pharmaceuticals on Monday said it has inked a licensing pact with Glenmark Pharmaceuticals to co-market diabetes drug Remogliflozin Etabonate in the country. 7-Bromo-3,4-dihydro-2H-benzo[b][1,4]oxazine hydrochloride manufacturer From a global perspective, China’s API companies have also performed well. According to the report of the American Transparent Medicine website, in 2016 the top ten pharmaceutical companies in the global API market, Chinese pharmaceutical companies accounted for 6 seats. 7-Bromo-3,4-dihydro-2H-benzo[b][1,4]oxazine hydrochloride supplier The Company��s immuno-regulatory product candidates include ProTmune, a pharmacologically modulated, donor cell graft that is currently being evaluated in a Phase 2 clinical trial for the prevention of graft-versus-host disease, and a myeloid-derived suppressor cell immunotherapy for promoting immune tolerance in patients with immune disorders. Fate Therapeutics is headquartered in San Diego, CA. 7-Bromo-3,4-dihydro-2H-benzo[b][1,4]oxazine hydrochloride vendor Mankind Pharmaceuticals on Monday said it has inked a licensing pact with Glenmark Pharmaceuticals to co-market diabetes drug Remogliflozin Etabonate in the country. 7-Bromo-3,4-dihydro-2H-benzo[b][1,4]oxazine hydrochloride factory The Company��s immuno-regulatory product candidates include ProTmune, a pharmacologically modulated, donor cell graft that is currently being evaluated in a Phase 2 clinical trial for the prevention of graft-versus-host disease, and a myeloid-derived suppressor cell immunotherapy for promoting immune tolerance in patients with immune disorders. Fate Therapeutics is headquartered in San Diego, CA.